SymBio Pharmaceuticals Limited
Notice regarding the completion of the acquisition and cancellation of the 58th, 66th and 67th stock acquisition rights, and the payment of the issue price for the 70th and 71st stock acquisition rights (with exercise price adjustment clause) issued to a third party
Acquisition and cancellation of stock acquisition rights completed; allocation of the 70th and 71st stock acquisition rights to EVO FUND. Total issue amount: 2,880,000 yen; potential shares: 96,000,000 shares; exercise price adjustment clause; exercise period: 2026/09/03–2029/09/03. Estimated funds raised: 6,768,880,000 yen.
Key Figures
- Total number of issued stock acquisition rights: 960,000 units (70th: 480,000 units, 71st: 480,000 units)
- Potential shares: 96,000,000 shares (100 shares per stock acquisition right)
- Total issue price: 2,880,000 yen
AI要約
Section heading
This news release covers the status of the acquisition and cancellation of stock acquisition rights, and the issuance of the 70th and 71st stock acquisition rights to a third party. It discloses the completion of acquisition and cancellation of the 58th, 66th and 67th stock acquisition rights, the third-party allocation to EVO FUND, and outlines the total number of issuances, issue price, potential shares, exercise period, and adjustment terms.
Second section heading
The exercise price adjustment clause governs the issuance conditions, with conditions based on the closing price on the adjustment date. The allocation is a third-party allocation, and the parties have entered into a purchase agreement and a total-underwriting agreement. Attention should be paid to potential effects on shareholder value, dilution, and exercise activity during the issuance period.
SymBio Pharmaceuticals Limited
Company overview · Stock price · Financial data · All IR
